<DOC>
	<DOCNO>NCT01105507</DOCNO>
	<brief_summary>This study ass safety , tolerability efficacy canakinumab treatment Canadian patient diagnose cryopyrin-associated periodic syndrome period 18 month .</brief_summary>
	<brief_title>The Safety Efficacy Canakinumab Patients Aged 4 Years Older Diagnosed With Cryopyrin-associated Periodic Syndromes ( CAPS ) Canada</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Male female patient least 4 year age time screen visit 2 . Patient 's informed consent &gt; = 18 year age assessment perform 3 . Parent legal guardian 's write informed consent child 's assent , appropriate , required assessment perform patient &lt; 18 year age . 4 . Patients diagnosis CAPS : FCAS/FCU , MWS , NOMID/CINCA 5 . Body weight &gt; = 15 kg 6 . Able communicate investigator comply requirement study ( child parent assist necessary ) 1 . Patient pregnant breastfeeding . Women childbearing potential must negative urine pregnancy test baseline 2 . Patient childbearing potential ( man woman ) unwilling use double barrier method contraception . It require double barrier method contraception use ( i.e . condom spermicide diaphragm spermicide ) patient childbearing potential ( man woman ) regardless whether hormonal agent also use method contraception . 3 . Participation clinical investigation within 4 week prior dose 4 . Live vaccination within 3 month prior start trial , trial 3 month follow last dose . 5 . History significant medical condition , Investigator 's opinion would exclude patient participate trial ( discuss Novartis case case basis case uncertainty ) . 6 . History drug alcohol abuse within 12 month prior dose 7 . History hypersensitivity study drug drug similar chemical class `` Other protocoldefined inclusion/exclusion criterion may apply ''</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Canakinumab</keyword>
	<keyword>Cryopyrin-associated periodic syndrome</keyword>
	<keyword>Familial Cold Autoinflammatory Syndrome ( FCAS )</keyword>
	<keyword>Familial Cold Urticaria ( FCU )</keyword>
	<keyword>Muckle-Wells Syndrome ( MWS )</keyword>
	<keyword>Neonatal-Onset Multisystem Inflammatory Disease ( NOMID )</keyword>
	<keyword>Chronic Infantile Neurological</keyword>
	<keyword>Cutaneous</keyword>
	<keyword>Articular Syndrome ( CINCA )</keyword>
	<keyword>Treatment patient diagnose CAPS ( Cryopyrin associate periodic syndrome )</keyword>
</DOC>